Developing a blood test to help diagnose sarcoidosis earlier
Sarcoidosis is an inflammatory disease that can affect multiple organs, most commonly the lungs and lymph nodes. There is no single definitive test: diagnosis relies on clinical assessment, imaging, laboratory tests and invasive procedures such as biopsies.
Anaxa is developing a blood test that detects Biomarker 143 to support evaluation of patients with suspected sarcoidosis. The company is refining the assay and validating preliminary data; clinical validation studies are planned.
What stands out about Anaxa
Anaxa reports elevated Biomarker 143 in sarcoidosis patient samples, with findings confirmed using bead-based assays and ELISA.
Anaxa identifies itself as a Karolinska Institutet spin-off, building on research in translational immunology.
Co-founder Anna Smed Sörensen is a professor of translational immunology whose research includes inflammatory lung disease.
Co-founder Albert Elfström founded corporate-finance firm Inter Nos in 2004 and was a founding partner of MLT Corporate Finance from 2016.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.